论文部分内容阅读
我国是食管癌的高发地区之一,2008年WHO的资料显示,我国食管癌的发生率为16.7/10万,其病死率也高达13.4/10万。近年来随着肿瘤分期方法的完善、手术水平的提高、新辅助及辅助治疗的应用等,食管癌患者的预后得到了一定的改善。一、新辅助化疗单独化疗在新辅助治疗中的作用已经被广泛探索。其中美国的RTOG 8911研究和英国医学研究委员会的MRC OEO2研究是其中最大的两个随机对照
China is one of the high incidence areas of esophageal cancer. According to WHO data in 2008, the incidence rate of esophageal cancer in China is 16.7 / 100000, and its case fatality rate is as high as 13.4 / 100000. In recent years, with the improvement of tumor staging method, the improvement of operation level, the application of neoadjuvant and adjuvant therapy, the prognosis of patients with esophageal cancer has been improved to a certain extent. First, neoadjuvant chemotherapy The role of chemotherapy alone in neoadjuvant therapy has been extensively explored. Among them, RTOG 8911 in the United States and MRC OEO2 in the British Medical Research Council are the two largest randomized controlled trials